Neologics Bioscience | ApexOnco - Clinical Trials news and analysis

x

“The team is super responsive to my inquiries and suggestions”

Chief Business Officer

US public biotech company

Click here for more information

Trial results

31 January 2024

Novartis calls time on TIM-3 and HIF2α

The company’s move could be a warning for rivals including GSK, AstraZeneca and Incyte.

Subscribe to Neologics Bioscience